Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Cervical cancer remains a leading cause of mortality among women in low- and middle-income countries. In Mexico it represents the second cancer with higher mortality. Advanced stages frequently cause obstructive nephropathy and acute kidney injury (AKI), leading to complex decisions regarding renal replacement therapy (RRT). In this setting, the nephrologist must balance clinical indications with ethical considerations, as RRT may offer limited benefit in patients with poor oncologic prognosis.
Objective: To identify predictors of RRT indication and discuss clinical futility in advanced cervical cancer with obstructive nephropathy.
A retrospective study was conducted including 22 women with histologically confirmed cervical cancer and renal dysfunction treated at the “Dr. José Eleuterio González” University Hospital, Monterrey, Mexico between September 2024 and July 2025. Variables analyzed included age, cancer stage, renal function parameters (eGFR, TFG), polyuric phase, and prognosis. Logistic regression identified independent predictors of RRT requirement.
Median age was 37 years (IQR 22). Advanced stages predominated (IVA 31.8%, IIIB 22.7%). Median baseline creatinine was 1.3 mg/dL, rising to 8.7 mg/dL at admission; median eGFR was 47.8 mL/min/1.73m².RRT was required in 45.5% of patients, mainly for severe azotemia (18.2%) and anuria (9.1%). The use of RRT increased with cancer stage—40–50% in IIB–IIIB versus 57.1% in IVA and 66.7% in IVB. (table 1) The logistic regression model (age, stage, eGFR, GFR, polyuric phase) significantly predicted RRT requirement (ΔΧ² = 12.75, p = 0.026; Nagelkerke R² = 0.607; AUC = 0.89). Lower eGFR (OR = 0.64) and polyuric phase (OR = 2.25) were associated with higher RRT likelihood. (table 2)
Hydronephrosis laterality correlated with stage: early stages showed heterogeneous patterns (unilateral or bilateral), whereas advanced stages exhibited predominantly bilateral hydronephrosis (42.9% in IVA; 66.7% in IVB). This distribution reflects extensive urinary tract compromise and minimal potential for renal recovery.
Although renal parameters and the polyuric phase strongly predict RRT requirement, therapeutic decisions should not rely only on biochemical criteria. In patients with advanced cervical cancer, initiating RRT may represent therapeutic futility when life expectancy and quality of life are minimal. Recognizing this boundary allows nephrologists to redirect care toward ethical management, emphasizing shared decision-making with oncology and palliative care teams.
